Paul A. Lapchak

Paul A. Lapchak, Ph.D. has extensive experience in the field of translational medicine, with a focus on neurodegenerative diseases and stroke. Paul A. currently serves as the Global Head of Translational Development at Paradigm Biopharmaceuticals, where they are responsible for non-clinical support and integration of data from preclinical studies. Prior to this, they held positions at BrainXell, Inc., where they played a key role in driving the translational science of projects and expanding the scope of induced pluripotent stem cell (iPSC) research for clinical development plans. Paul A. also has experience in research and development of small molecules and stem cell therapy at Neurocore LLC. Dr. Lapchak's earlier career includes positions at Cedars-Sinai, where they were involved in drug and device development for stroke and served as the Director of Translational Research. Paul A. also held roles as a Research Scientist and Principal Investigator at the Veterans Medical Research Foundation and UC San Diego. Additionally, they worked as a Research Scientist, directing the Parkinson's Disease Program, at Amgen, and as a Research Scientist at Johnson & Johnson Vision.

Paul A. Lapchak, Ph.D. completed their Bachelor's degree in Chemistry-Medicinal Chemistry from Concordia University in 1984. Paul A. then pursued a Doctor of Philosophy (Ph.D.) in Pharmacology from McGill University, which they successfully obtained in 1988.